DSS Takara Bio India Pvt. Revenue and Competitors

New Delhi, India

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DSS Takara Bio India Pvt.'s estimated annual revenue is currently $5.9M per year.(i)
  • DSS Takara Bio India Pvt.'s estimated revenue per employee is $79,595

Employee Data

  • DSS Takara Bio India Pvt. has 74 Employees.(i)
  • DSS Takara Bio India Pvt. grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.5M127-4%N/AN/A
#2
$17.3M22318%N/AN/A
#3
$11.1M14334%N/AN/A
#4
$6.9M879%N/AN/A
#5
$8.7M10110%N/AN/A
#6
$19.6M2248%N/AN/A
#7
$12M1558%N/AN/A
#8
$17.1M2005%N/AN/A
#9
$11.5M1329%N/AN/A
#10
$6.9M798%N/AN/A
Add Company

DSS Takara Bio India is a joint venture between DSS Imagetech Pvt. Ltd. and Takara Bio Inc. This joint venture was established in 2011 to bring world-class quality molecular biology tools and research kits to the doorstep of Indian Scientific Community making them readily available and affordable in the Indian biotechnology market. We market Takara Bio, Clontech, Cellartis, Rubicon and WaferGen products to customers throughout the country. Additionally, we represent comprehensive product lines from our Partnered brands like Exiqon, Macherey-Nagel, IBL and PromoCell. At present, we are manufacturing Takara Bio branded routine molecular biology products in India at our manufacturing unit located in New Delhi. Our head office is located in New Delhi. We have branch offices located at nine other major cities in India - Lucknow, Chandigarh, Kolkata, Mumbai, Pune, Bangalore, Hyderabad, Chennai, Thiruvananthapuram www.dsstakarabio.com Partnered Brands: Macherey-nagel: http://www.mn-net.com/ Exiqon: http://www.exiqon.com/ IBL: http://www.ibl-japan.co.jp/en/ PromoCell: http://www.promocell.com/

keywords:N/A

N/A

Total Funding

74

Number of Employees

$5.9M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.8M74-4%N/A
#2
$6.1M757%N/A
#3
$9.1M750%N/A
#4
$4M7510%N/A
#5
$6.7M761%N/A